EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Haemophilia B in Algeria: Realities and therapeutic perspectives

Mohamed Salim Nekkal iD, Naima Mesli, Fatiha Grifi, Nacira Cherif, Zohra Ouchenane, Mohamed Said Bettayeb

Haemophilia · 2023

DOI: 10.1111/hae.14827 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Haemophilia, 2023. Verfasst von Mohamed Salim Nekkal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Issad Hassani Hospital, Algiers, Algeria. Hauptthemen laut MEDLINE: Hemophilia B, Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Haemophilia B is a debilitating hereditary coagulation disorder characterized by prolonged or spontaneous episodes of bleeding caused by a deficiency of endogenous factor IX. In Algeria, even though many studies are being carried out to evaluate the prevalence and management of haemophilia B, there is a paucity of locally published literature that can be used to understand the most recent information on the disease's epidemiology, diagnostic techniques and treatment options.

Aims

The aim of this manuscript is to raise awareness among patients and family clinicians about current practices, recent developments and unmet needs related to haemophilia B in Algeria.

Methods

A comprehensive literature search was conducted through online scientific databases to review publications regarding haemophilia B in Algeria. Exclusions of the review include case studies, interregional comparisons, abstract‐only papers and studies outside the range of 2012–2022.

Results

The findings discussed relate to the epidemiology of haemophilia B in Algeria, the clinical diagnostic process, disease symptoms, the benefits of molecular and genetic testing, advancements in prophylactic care, as well as unmet needs hindering the progression of optimal haemophilia B management.

Conclusion

These findings are crucial to encourage the maintenance of national registries with updated epidemiological data, facilitate early and timely detection of disease symptoms, improve the provision of diagnostic facilities and enhance the overall treatment landscape for better patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia BHemophilia AHumansAlgeriaFactor IXHemorrhage

Stichwörter der Autor:innen

Algeriadiagnosisdisease managementepidemiologyhaemophilia Brecommendations

Substanzen

Factor IX

Autor:innen und Institutionen

  • Issad Hassani Hospital, Algiers, Algeria.
  • Dr Tidjani Damerdji University Hospital, Tlemcen, Algeria.
  • Annaba University Hospital, Annaba, Algeria.
  • Constantine Dr Benbadis University Hospital, Constantine, Algeria.
  • Hospital Business and Rare Diseases, Pfizer Inc. Ltd, Algiers, Algeria.

ORCID-Profile: Mohamed Salim Nekkal

Förderung

  • Pfizer

Zitieren

APA

Nekkal, M. S., Mesli, N., Grifi, F., Cherif, N., Ouchenane, Z., & Bettayeb, M. S. (2023). Haemophilia B in Algeria: Realities and therapeutic perspectives. Haemophilia. https://doi.org/10.1111/hae.14827

Vancouver

Nekkal MS, Mesli N, Grifi F, Cherif N, Ouchenane Z, Bettayeb MS. Haemophilia B in Algeria: Realities and therapeutic perspectives. Haemophilia. 2023. doi:10.1111/hae.14827

BibTeX
@article{Nekkal2023,
  author = {Nekkal, Mohamed Salim and Mesli, Naima and Grifi, Fatiha and Cherif, Nacira and Ouchenane, Zohra and Bettayeb, Mohamed Said},
  title = {Haemophilia B in Algeria: Realities and therapeutic perspectives},
  journal = {Haemophilia},
  year = {2023},
  doi = {10.1111/hae.14827}
}
Kostenlos starten →